Vitamin D deficiency: Consequence or cause of CKD?

Clinical Journal of the American Society of Nephrology

Volumn 8, Issue 11, 2013, Pages 1844-1846

  de Boer, Ian H ^a   Thadhani, Ravi ^b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CALCIFEDIOL; CALCITRIOL; COLECALCIFEROL; CREATININE; ERGOCALCIFEROL; FIBROBLAST GROWTH FACTOR 23; PARATHYROID HORMONE; VITAMIN D RECEPTOR;

BONE TURNOVER; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL (TOPIC); DRUG SUBSTITUTION; EDITORIAL; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FAILURE; NONHUMAN; SIDE EFFECT; VITAMIN D DEFICIENCY; VITAMIN SUPPLEMENTATION;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; FEMALE; HUMANS; KIDNEY; MALE; RENIN-ANGIOTENSIN SYSTEM; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 84887282091     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.09480913     Document Type: Editorial

References (26)

1. Kodicek E, Lawson DE, Wilson PW: Biological activity of a polar metabolite of vitamin D. Nature 228: 763-764, 1970
2. Omdahl J, Holick M, Suda T, Tanaka Y, DeLuca HF: Biological activity of 1,25-dihydroxycholecalciferol. Biochemistry 10: 2935-2940, 1971
3. Lawson DE, Fraser DR, Kodicek E, Morris HR, Williams DH: Identification of 1,25-dihydroxycholecalciferol, a new kidney hormone controlling calcium metabolism. Nature 230: 228-230, 1971
4. Brickman AS, Coburn JW, Norman AW: Action of 1,25-dihydroxycholecalciferol, a potent, kidney-produced metabolite of vitamin D, in uremic man. N Engl J Med 287: 891-895, 1972
5. Slatopolsky E, Weerts C, Thielan J, Horst R, Harter H, Martin KJ: Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients. J Clin Invest 74: 2136-2143, 1984
6. Andress DL, Norris KC, Coburn JW, Slatopolsky EA, Sherrard DJ: Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure. N Engl J Med 321: 274-279, 1989
7. Schwarz U, Amann K, Orth SR, Simonaviciene A, Wessels S, Ritz E: Effect of 1,25 (OH)2 vitamin D3 on glomerulosclerosis in subtotally nephrectomized rats. Kidney Int 53: 1696-1705, 1998
8. Kuhlmann A, Haas CS, Gross ML, Reulbach U, Holzinger M, Schwarz U, Ritz E, Amann K: 1,25-Dihydroxyvitamin D3 decreases podocyte loss and podocyte hypertrophy in the subtotally nephrectomized rat. AmJ Physiol Renal Physiol 286: F526-F533, 2004
9. Zhang Z, Zhang Y, Ning G, Deb DK, Kong J, Li YC: Combination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy: Blockade of compensatory renin increase. Proc Natl Acad Sci U S A 105: 15896-15901, 2008
10. Branisteanu DD, Leenaerts P, van Damme B, Bouillon R: Partial prevention of active Heymann nephritis by 1 alpha, 25 dihydroxyvitamin D3. Clin Exp Immunol 94: 412-417, 1993
11. Li YC, Kong J, WeiM, ChenZF, Liu SQ, CaoLP: 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 110: 229-238, 2002
12. Hirata M, Makibayashi K, Katsumata K, Kusano K, Watanabe T, Fukushima N, Doi T: 22-Oxacalcitriol prevents progressive glomerulosclerosis without adversely affecting calcium and phosphorus metabolism in subtotally nephrectomized rats. Nephrol Dial Transplant 17: 2132-2137, 2002
13. Wang Y, Deb DK, Zhang Z, Sun T, LiuW, Yoon D, Kong J, Chen Y, Chang A, Li YC: Vitamin D receptor signaling in podocytes protects against diabetic nephropathy. J Am Soc Nephrol 23: 1977-1986, 2012
14. de Zeeuw D, Agarwal R, Amdahl M, Audhya P, Coyne D, Garimella T, Parving HH, Pritchett Y, Remuzzi G, Ritz E, Andress D: Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): A randomised controlled trial. Lancet 376: 1543-1551, 2010
15. de Borst MH, Hajhosseiny R, Tamez H, Wenger J, Thadhani R, Goldsmith DJ: Active vitamin D treatment for reduction of residual proteinuria: A systematic review [published online ahead of print August 8, 2013]. J AmSoc Nephrol doi:10.1681/ASN.2013030203
16. ThadhaniR, AppelbaumE, PritchettY, Chang Y, Wenger J, Tamez H, Bhan I, Agarwal R, Zoccali C, Wanner C, Lloyd-Jones D, Cannata J, Thompson BT, Andress D, Zhang W, Packham D, Singh B, ZehnderD, Shah A, Pachika A, ManningWJ, Solomon SD: Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: The PRIMO randomized controlled trial. JAMA 307: 674-684, 2012
17. Fernández-Juárez G, Luño J, Vicente Barrio V, García de Vinuesa S, Praga M, Goicoechea M, Lahera V, Casas L, Oliva J; on behalf of the PRONEDI Study Group: 25(OH) vitamin D levels and renal disease progression in patients with type 2 diabetic nephropathy and blockade of the renin-angiotensin system. Clin J Am Soc Nephrol 8: 1870-1876, 2013
18. Ravani P, Malberti F, Tripepi G, Pecchini P, Cutrupi S, Pizzini P, Mallamaci F, Zoccali C: Vitamin D levels and patient outcome in chronic kidney disease. Kidney Int 75: 88-95, 2009
19. de Boer IH, Katz R, Chonchol M, Ix JH, Sarnak MJ, Shlipak MG, Siscovick DS, Kestenbaum B: Serum 25-hydroxyvitamin D and change in estimated glomerular filtration rate. Clin J Am Soc Nephrol 6: 2141-2149, 2011
20. Kendrick J, Cheung AK, Kaufman JS, Greene T, RobertsWL, Smits G, Chonchol M; HOST (Homocysteinemia in Kidney and End Stage Renal Disease) Study Investigators: Associations of plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D concentrations with death and progression to maintenance dialysis in patientswith advanced kidney disease. AmJ KidneyDis 60: 567-575, 2012
21. de Boer IH, Sachs MC, Cleary PA, Hoofnagle AN, Lachin JM, Molitch ME, Steffes MW, Sun W, Zinman B, Brunzell JD; Diabetes Control and Complication Trial/Epidemiology of Diabetes Interventions and Complications Study Research Group: Circulating vitamin D metabolites and kidney disease in type 1 diabetes. J Clin Endocrinol Metab 97: 4780-4788, 2012
22. Wang TJ, Zhang F, Richards JB, Kestenbaum B, van Meurs JB, Berry D, Kiel DP, Streeten EA, Ohlsson C, Koller DL, Peltonen L, Cooper JD, O'Reilly PF, Houston DK, Glazer NL, Vandenput L, Peacock M, Shi J, Rivadeneira F, McCarthy MI, Anneli P, de Boer IH, Mangino M, Kato B, Smyth DJ, Booth SL, Jacques PF, Burke GL, Goodarzi M, Cheung CL, Wolf M, Rice K, Goltzman D, Hidiroglou N, Ladouceur M, Wareham NJ, Hocking LJ, Hart D, Arden NK, Cooper C, Malik S, FraserWD, Hartikainen AL, Zhai G, Macdonald HM, Forouhi NG, Loos RJ, Reid DM, Hakim A, Dennison E, Liu Y, Power C, Stevens HE, Jaana L, Vasan RS, SoranzoN, Bojunga J, Psaty BM, LorentzonM, Foroud T, Harris TB, Hofman A, Jansson JO, Cauley JA, Uitterlinden AG, Gibson Q, Järvelin MR, Karasik D, Siscovick DS, Econs MJ, Kritchevsky SB, Florez JC, Todd JA, Dupuis J, Hyppönen E, Spector TD: Common genetic determinants of vitamin D insufficiency: A genome-wide association study. Lancet 376: 180-188, 2010
23. de Boer IH, Sachs M, Hoofnagle AN, Utzschneider KM, Kahn SE, Kestenbaum B, Himmelfarb J: Paricalcitol does not improve glucose metabolism in patients with stage 3-4 chronic kidney disease. Kidney Int 83: 323-330, 2013
24. Robinson-Cohen C, Hoofnagle AN, Ix JH, Sachs MC, Tracy RP, Siscovick DS, Kestenbaum BR, de Boer IH: Racial differences in the association of serum 25-hydroxyvitamin D concentration with coronary heart disease events. JAMA 310: 179-188, 2013
25. Levin GP, Robinson-Cohen C, de Boer IH, Houston DK, Lohman K, Liu Y, Kritchevsky SB, Cauley JA, Tanaka T, Ferrucci L, Bandinelli S, Patel KV, Hagström E, Michaëlsson K, Melhus H, Wang T, Wolf M, Psaty BM, Siscovick D, Kestenbaum B: Genetic variants and associations of 25-hydroxyvitamin D concentrations with major clinical outcomes. JAMA 308: 1898-1905, 2012
26. de Boer IH, Kestenbaum B: Vitamin D in chronic kidney disease: Is the jury in? Kidney Int 74: 985-987, 2008